Jorge Bezerra

31 statements · 1 topic · summaries given as host listed separately

Biliary Atresia · guest expert

Featured statements

▶ Ep 8 · 4:16
In United States and Europe by two weeks of age, if the baby still has jaundice, the pediatrician or whoever's seeing the patient needs to fractionate the Billy Rubin. If the direct or conjugated fraction is up, think about the pathologic jaundice.
▶ Ep 14 · 3:30
If they say the baby has normal stool color, we want to see it because there have been many cases in which the parents thought it was okay, but to us it was a colic stool.

Nothing matches these filters — clear the search or widen the filters.

Jorge's statements about Biliary Atresia 31 statements

Open the Biliary Atresia collection →

Biliary Atresia - Clinical Practice Updates

▶ Ep 8 · 3:22
epidemiological In the US and Europe, alpha-1 antitrypsin deficiency is the most common cause of neonatal cholestasis in the differential diagnosis ↗
▶ Ep 8 · 4:16
guideline By two weeks of age, if the baby still has jaundice, the pediatrician needs to fractionate the bilirubin; if the direct or conjugated fraction is elevated, think about pathologic jaundice ↗
▶ Ep 8 · 4:16
quote In United States and Europe by two weeks of age, if the baby still has jaundice, the pediatrician or whoever's seeing the patient needs to fractionate the Billy Rubin. If the direct or conjugated fraction is up, think about the pathologic jaundice. ↗
▶ Ep 8 · 12:20
quote It is very uncommon to have a baby with biliary atresia and a low MMP7. ↗
▶ Ep 8 · 12:20
clinical Cutoff values for MMP7 changed depending on reports from Asia, with much lower cutoff levels reported from Taiwan and China ↗
▶ Ep 8 · 12:51
clinical The MMP7 assay is run every other day and is a six-hour assay ↗
▶ Ep 8 · 24:04
opinion Liver biopsy has additional value to quantify inflammation and use that information to personalize treatment ↗

Biliary Atresia Part II

▶ Ep 14 · 1:50
guideline American Academy of Pediatrics recommends fractionation of bilirubin for any baby with persistent jaundice beyond two weeks of age, with referral to pediatric gastroenterologist if direct bilirubin is elevated ↗
▶ Ep 14 · 1:50
guideline American Academy of Pediatrics recommends fractionation of bilirubin for any baby with persistent jaundice beyond two weeks of age, with referral to pediatric gastroenterologist if direct bilirubin is elevated ↗
▶ Ep 14 · 2:31
clinical Cincinnati protocol: ultrasound and blood work same day, alpha-1 antitrypsin testing, liver biopsy if alpha-1 normal and acholic stool present, decision on Kasai within 5-7 days ↗
▶ Ep 14 · 2:31
clinical Cincinnati protocol: ultrasound and blood work same day, alpha-1 antitrypsin testing, liver biopsy if alpha-1 normal and acholic stool present, decision on Kasai within 5-7 days ↗
▶ Ep 14 · 3:30
clinical Parents reporting normal stool color must show the stool for verification, as many parents misidentify acholic stools as normal ↗
▶ Ep 14 · 3:30
quote If they say the baby has normal stool color, we want to see it because there have been many cases in which the parents thought it was okay, but to us it was a colic stool. ↗
▶ Ep 14 · 3:30
quote If they say the baby has normal stool color, we want to see it because there have been many cases in which the parents thought it was okay, but to us it was a colic stool. ↗
▶ Ep 14 · 3:30
clinical Parents reporting normal stool color must show the stool for verification, as many parents misidentify acholic stools as normal ↗
▶ Ep 14 · 4:03
epidemiological MMP7 (matrix metalloprotein 7) ELISA on serum predicts biliary atresia with 96% positive predictive value and 98% negative predictive value in Wuhan cohort study (in press) ↗
▶ Ep 14 · 4:03
quote MMP7 alone, at a specific curve level, can predict biliary atresia with a positive predictive value of about 96% and negative predictive value of about 98%. ↗
▶ Ep 14 · 4:03
epidemiological MMP7 (matrix metalloprotein 7) ELISA on serum predicts biliary atresia with 96% positive predictive value and 98% negative predictive value in Wuhan cohort study (in press) ↗
▶ Ep 14 · 4:03
quote MMP7 alone, at a specific curve level, can predict biliary atresia with a positive predictive value of about 96% and negative predictive value of about 98%. ↗
▶ Ep 14 · 5:48
epidemiological START trial (US multicenter, double-blind, placebo-controlled): no significant difference in jaundice clearance at 6 months between steroid and placebo groups in all comers (58% vs 48%, p>0.05) ↗
▶ Ep 14 · 5:48
epidemiological Davenport UK trial showed improvement in jaundice clearance and decrease in bilirubin and liver enzymes with high-dose steroids versus no steroid ↗
▶ Ep 14 · 14:32
epidemiological START trial design was adequately powered as designed; randomized phase had N=70 per arm, larger than Davenport's randomized phase (N=18 steroid, N=19 placebo) ↗
▶ Ep 14 · 14:32
epidemiological START trial design was adequately powered as designed; randomized phase had N=70 per arm, larger than Davenport's randomized phase (N=18 steroid, N=19 placebo) ↗
▶ Ep 14 · 16:30
epidemiological START trial documented that serious adverse events occurred earlier in steroid group compared to placebo during the period of steroid administration, but no difference in total SAE frequency ↗
▶ Ep 14 · 16:30
epidemiological START trial documented that serious adverse events occurred earlier in steroid group compared to placebo during the period of steroid administration, but no difference in total SAE frequency ↗
▶ Ep 14 · 20:12
clinical Aggressive nutrition management is key: maintain adequate weight gain with concentrated formula or NG supplementation as needed, plus fat-soluble vitamin replacement ↗
▶ Ep 14 · 20:12
clinical Aggressive nutrition management is key: maintain adequate weight gain with concentrated formula or NG supplementation as needed, plus fat-soluble vitamin replacement ↗
▶ Ep 14 · 30:20
clinical For patients who never clear jaundice post-Kasai: focus on aggressive nutrition and proceed to liver transplant evaluation; nutritional support is key driver in determining post-transplant complications ↗
▶ Ep 14 · 30:20
clinical For patients who never clear jaundice post-Kasai: focus on aggressive nutrition and proceed to liver transplant evaluation; nutritional support is key driver in determining post-transplant complications ↗
▶ Ep 14 · 40:38
clinical Cincinnati has unpublished animal model data showing targeted anti-fibrotic therapy produces remarkable decrease in collagen deposition and hepatic fibrosis ↗
▶ Ep 14 · 40:38
clinical Cincinnati has unpublished animal model data showing targeted anti-fibrotic therapy produces remarkable decrease in collagen deposition and hepatic fibrosis ↗

Summaries Jorge gave as host · 2 summaries

Recaps of other experts' statements, not Jorge's own clinical position.

Summaries Jorge gave as host · Biliary Atresia 2 summaries

Open the Biliary Atresia collection →

Biliary Atresia Part II

▶ Ep 14 · 5:48
host summary Jorge Bezerra summarizing the discussion: START trial (US multicenter, double-blind, placebo-controlled): no significant difference in jaundice clearance at 6 months between steroid and placebo groups in all comers (58% vs 48%, p>0.05) ↗
▶ Ep 14 · 5:48
host summary Jorge Bezerra summarizes what Dr. Mark Davenport said: Davenport UK trial showed improvement in jaundice clearance and decrease in bilirubin and liver enzymes with high-dose steroids versus no steroid ↗